Recent

% | $
Quotes you view appear here for quick access.

NQ Mobile Inc. Message Board

marketjudge 24 posts  |  Last Activity: Mar 27, 2015 7:11 AM Member since: Sep 13, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Results out..... SWING AND A MISS!

    by hugeman99 Mar 27, 2015 7:04 AM
    marketjudge marketjudge Mar 27, 2015 7:11 AM Flag

    RESULTS ARE GREAT!!!!!!!
    I TOLD YOU SO!

    Sentiment: Strong Buy

  • marketjudge marketjudge Mar 26, 2015 9:06 PM Flag

    At the end of the study, patients treated with the combination of OHR-102 plus Lucentis were still improving. The dramatic and early vision gains observed are believed to result in part from the regression of SHRM, which is widely considered to be a combination of neovascular tissue, pre-fibrotic material and other sub retinal exudative and inflammatory debris.

    "STILL IMPROVING"
    "DRAMATIC AND EARLY VISION GAINS"
    "RAPID REDUCTION IN SHRM"
    "DISEASE MODIFYING EFFECT" - FOR ALL THE PATIENT INCLUDING THE SUBGROUPS -
    "MEANINGFULL AND CLINICALL RELEVANT"- OH I THINK THIS IS STATISTICALLY SIGNIFICATNT-

    OHR-102 plus Lucentis® resulted in a meaningful and clinically relevant improvement in visual
    acuity compared with Lucentis monotherapy..

    O.K BILL DO YOU THINK BEING ABLE TO CONTROL THE DISEASE STATE IS STATISTICALLY
    SIGNIFICANT-I DO!

    Sentiment: Strong Buy

  • marketjudge marketjudge Mar 26, 2015 8:34 PM Flag

    I disagree, if you watched CNBC today you would have seen the interview with one of the top analysts in the bio tech field state that certain biotech stocks are underpriced due to misunderstood market fundamentals. OHRP is going after a very large market, with its platform to address diabetics as well. Its a sleeper I agree, but that is why I believe it is a great beat. They have proven that their products works. Give it time, and you will be rewarded.

    Sentiment: Strong Buy

  • WHY IS THIS STOCK TRADING AS THOUGH NONE OF THE TRIALS SHOWED ANY BENEFITS!
    I AM USING THIS AS A BUYING OPPORTUNITY. BASED ON THE PREVIOUS STUDY, I CAN NOT SEE THE DATA COMING IN NEGATIVE!

    AMD Data Summary
    •OHR-102 (0.2% Squalamine Lactate) eye drops in combination with PRN Lucentis leads to superior outcomes compared to PRN Lucentis monotherapy:
    –Improved Mean Visual Acuity
    –Improved 3/4/5 Line Vision Gains
    –Improved 20/40 and 20/32 Vision Function
    –Improved Anatomic Findings
    •Correlated with visual function
    –Effect achieved with BID topical medication
    •Completion of full study expected in Q1 2015
    •Phase 3 study initiation planned for first half 2015

    "IN THOSE PATIENTS TREATED WITH THE OHR-102 APPEARS TO PREVENT FUTHER DEVELOPMENT OF SHRM. IN THOSE PATIENTS TREATED WITH OHR-102 PLUS LUCENTIS COMBINATION, NONE EXPERIENNCED WORSENING IN SHRM OVER THE 9 MONTHS OF THE STUDY"!
    THIS MEANS THE DESEASE STATE PROGRESSION HAS HALTED. I

    Also presented were new data showing that treatment with OHR-102 appears to prevent further development of SHRM. In those patients treated with the OHR-102 plus Lucentis combination, none experienced worsening in SHRM over the 9 months of the study. In contrast, among Lucentis monotherapy patients, 15% of the overall group and 23% of the classic-containing CNV lesion group experienced worsening of SHRM by the end of the study

    Sentiment: Strong Buy

  • Reply to

    Load Up Boys And Girls

    by marketjudge Mar 25, 2015 11:09 AM
    marketjudge marketjudge Mar 25, 2015 7:48 PM Flag

    Oh Steven, did I get you upset, now I know why you have an SB in your name. You are acting like a little Silly #$%$. I spoke with Adam in investment services. Now as you know its not the end of the Quarter Yet. Be patient and stop acting silly. Take sixty three seconds and come down. If you forget this, just abbreviate your actions. StevenSB63!
    You wanted to go into the frying pan, YOU GOT IT!

    Sentiment: Strong Buy

  • Reply to

    Load Up Boys And Girls

    by marketjudge Mar 25, 2015 11:09 AM
    marketjudge marketjudge Mar 25, 2015 7:02 PM Flag

    I should not reply to messages such as this, but I am a New Yorker. So, her we go,
    If I wanted to spend $20 bucks, I would have paid you your regular fee to KISS MY_____________!
    LoL

    Sentiment: Strong Buy

  • marketjudge by marketjudge Mar 25, 2015 11:09 AM Flag

    I called INVESTOR INQUIRIES, the data is going to be out by Friday or latest Monday.
    I think that they will release the data Friday morning. They are getting the data
    reviewed by legal, and when that is done, it will be published.
    I am in baby!!!

    Sentiment: Strong Buy

  • BACKGROUND:

    BASED ON THE PHASE ONE STUDY I SEE NO REASON WHY PHASE 2 WILL NOT PE POSITIVE, EVEN WHEN YOU TAKE AWAY THE PROBABILTY OF SUCCESS BY CHANCE ALONE. MAJOR RUN COMING!
    METHODS AND RESULTS:
    Thirty-nine patients received intracoronary adeno-associated virus type 1/sarcoplasmic reticulum Ca(2+)-ATPase or placebo. Seven efficacy parameters were assessed in 4 domains: symptoms (New York Heart Association class, Minnesota Living With Heart Failure Questionnaire), functional status (6-minute walk test, peak maximum oxygen consumption), biomarker (N-terminal prohormone brain natriuretic peptide), and left ventricular function/remodeling (left ventricular ejection fraction, left ventricular end-systolic volume), plus clinical outcomes. The primary end point success criteria were prospectively defined as achieving efficacy at 6 months in the group-level (concordant improvement in 7 efficacy parameters and no clinically significant worsening in any parameter), individual-level (total score for predefined clinically meaningful changes in 7 efficacy parameters), or outcome end points (cardiovascular hospitalizations and time to terminal events). Efficacy in 1 analysis had to be associated with at least a positive trend in the other 2 analyses. This combination of requirements resulted in a probability of success by chance alone of 2.7%. The high-dose group versus placebo met the prespecified criteria for success at the group-level, individual-level, and outcome analyses (cardiovascular hospitalizations) at 6 months (confirmed at 12 months) and demonstrated improvement or stabilization in New York Heart Association class, Minnesota Living With Heart Failure Questionnaire, 6-minute walk test, peak maximum oxygen consumption, N-terminal prohormone brain natriuretic peptide levels, and left ventricular end-systolic volume. Significant increases in time to clinical events and decreased frequency of cardiovascular events were observed at 12 months.

    Sentiment: Strong Buy

  • In April CLND will touch the $50 Mark. This type of movement in stock price is normal.
    This week CLDN went below $24 only to recover yesterday and close above $27. Today's
    price movement is based on day traders taking short term profits. I would be concerned if
    we touched the $24 mark. This will not happen, look for closing today between $25.75-$26.10.

    Sentiment: Strong Buy

  • marketjudge by marketjudge Mar 20, 2015 10:15 AM Flag

    Last day before the weekend, and the bears are trying hard to get it back to 25-26 range. Actually this is a good sign! They want the shares, sorry boy's, cannot have any that i have!

    Sentiment: Strong Buy

  • marketjudge by marketjudge Mar 19, 2015 7:19 AM Flag

    April is around the corner, and the bears are really trying to get the price point down. As I said before, look at the trading pattern of BLUE about a two months before the big jump.

    Sentiment: Strong Buy

  • According to TipRanks, Piros is a 4-star analyst with an average return of 39.1% and a 100.0% success rate. Piros covers the Healthcare sector.

    Celladon Corp is a clinical-stage biotechnology company. The Company is engaged in developing treatments for heart failure, diabetes and neurodegenerative diseases.

    Sentiment: Strong Buy

  • marketjudge by marketjudge Mar 18, 2015 9:18 PM Flag

    Know boy's and girl's lets look at who is recommending the stock!
    Dr. Elemer Piros
    He does not give many recommendations, in fact during the last year he has done 5.
    And all five of those recommendation were 100% correct, not bad.

    Another fact to remember is that he Joined ROTH Capital this year, he need to establish himself. Does anyone think that his first recommendation with the ROTH CAPITAL would be based on hope, or concrete research. Does anyone think that he has lack of experience. Look at his history people. How many of us have that type of background. My background is pharmaceutical, I am the CEO of Health Path Pharmacy, Inc.
    Feel free to call me, get the number form my website. I see the potential in this stock, and more importantly I understand why Dr. Piros has a $70 price target. I hope everyone on this Board understand why.
    analysis.
    Elemer Piros joins Roth biotech team

    February 19, 2015 by stephenkilmer ·
    Elemer Piros has joined Roth Capital Partners as a senior research analyst covering the biotechnology sector.

    Prior to joining Roth, Dr. Piros was interim CEO of eMMUNITY, an immunotherapy startup company. He was previously a senior biotechnology analyst at Rodman & Renshaw and Burrill Securities.

    Elemer Piros, Ph.D.

    Dr. Piros was ranked as the No. 1 biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, both based on stock portfolio performance.

    In a statement, Byron Roth, CEO of Roth, said Mr. Piros brings a wealth of industry expertise and relationships to Roth that will add important resources to its platform.

    Mr. Piros said Roth is a highly regarded investment bank with a strong track record in healthcare. “I am very impressed by the quality and depth of the Roth research universe. My goal is to provide a significant contribution by analyzing companies with cutting-edge medical research and translating science and clinical findings to actionable investment recommendations.”

    Sentiment: Strong Buy

  • Similar trading pattern as BLUE
    Oct 8 2014 blue was $35.29 Per Share
    By Oct 13 2014 BLUE went down to $30.68
    On Oct 30 2014 BLUE RECOVERED $41.29
    ON DEC 9, 2014 RESULT SENT BLUE TO $84.29
    THIS PRICE MOVEMENT IS A CLASSIC SHAKE-DOWN.
    PRICE WENT UP TO $27 BEARS PUSHING STOCK DOWN
    TO ACQUIRE MORE SHARES. GREAT STRATEGY!
    BY THE WAY-CLDN WAS POTENTIALLY A BIGGER MARKET
    THAN BLUE.
    CLDN IS THE FIRST COMPANY TO GET FDA BLESSING IN GENE THERAPY
    (Breakthrough Therapy status from FDA) PLUS FAST TRACK STATUS
    O.K NOW TELL ME WHAT IS SHOULD DO!!

  • marketjudge marketjudge Mar 18, 2015 5:09 PM Flag

    If you got rich because of a $4.00 move, you must be living in a poor life!

    Sentiment: Strong Buy

  • marketjudge by marketjudge Mar 18, 2015 3:33 PM Flag

    CLDN has taken a hit, but the fundamentals are the same.
    Great pipeline with a huge market potential.
    Here are some of the analysts recommending the
    stock.
    Elemer Piros,
    Roth Capital
    Analyst
    Ranked #1234 out of 3551 Analysts (Ranked #2338 out of 7854 total experts)
    Price Target $70
    5 out of 5 recommendations had positive returns in the last year.

    Today Portfolio Grader, InvestorPlace
    ISSUED A BUY RECOMMENDATION

    Zacks Equity Research ,Ranked #1173 out of 4303 Bloggers (Ranked #2476 out of 7854 total experts)
    ISSUED BUY RECOMMENDATION 13 DAYS AGO

    Stock Reversals, Seeking Alpha
    ISSUED A BUY RECOMMENDTION AND STATED THE FOLLOWING!
    Just remember CLDN has a fast track designation and
    Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside

    Jan. 7, 2015 5:10 PM ET | 36 comments | About: Celladon Corporation (CLDN)

    Summary
    •Market capitalization leaves room for a lot of upside.
    •Piper Jaffray believes cardiovascular gene therapy could explode on scene in 2015.
    •350,000-525,000 patient population with Breakthrough Therapy status from FDA.
    •Results from Phase 2b trial due in April; the company is ramping up production capacity now.

    We believe Celladon (NASDAQ:CLDN) has the potential to be a wealth builder for early investors ahead of its April Phase 2b data release. The company has been increasing credit lines, setting up manufacturing agreements and running test batches of its MYDICAR ahead of April. The upside in the market cap could be substantial.

    GILD HAS A MEDICATION THAT TREATS HEP C AND CHARGES ABOUT $50 -60k.-STOCK PRICE $100.
    NOW CLDN IS $24, AND IT WILL:
    Revenues: In an October 13 research report, Credit Suisse indicated that it expects upon approval that MYDICAR dosages would be $36,000 in the U.S. and $23,000 in the E.U. With a 350,000 patient population in the U.S. alone, not counting the E.U., the revenue potential upon an approval is well north of $1 billion.
    KNOW THE MARKET IS MUCH LARGER FOR CLDN!!!!!!!!!!

    Sentiment: Strong Buy

  • marketjudge marketjudge Mar 10, 2015 6:18 PM Flag

    Alpha Exposure writes about long term fundamental investment ideas," and invests in them as well." This author has substantial investment research experience.
    This is what is stated about the author. "AND INVESTS IN THEM AS WELL".
    The writer invests in short positions, all his recommendations are ALL negative.
    What exactly is he/she investing in. In fact the author is not reveled in the article.
    Why!!! Every recommendation made is fallowed by the name of the individual making it!
    In this situation no name, and disclosure is given that states "AND INVESTS IN THEM AS WELL".
    Is the negative recommendation given because the individual has a large short position that has not done well. When I read this article I notice no credit is given to SGMO, even with 200 million in cash, and multiple partnership, followed by FDA green light, this author is all NEGATIVE!!
    I guess he/she has been screwed big time trying to short this stock!

    Sentiment: Strong Buy

  • marketjudge marketjudge Mar 10, 2015 5:48 PM Flag

    These are the companies that this writer has stated they are negative on. This article was written by a short seller! Facts are translated for the benefit of forcing the stock price down. I respect the FDA's opinion on allowing the study to proceed. The is the ultimate stamp of approval.

    Sangamo Biosciences (SGMO)

    1 Ratings

    latest: Sell Today



    Ampio Pharmaceutical (AMPE)

    1 Ratings

    latest: Sell 1 month ago



    SFX Entertainment (SFXE)

    2 Ratings

    latest: Sell 4 months ago



    Parkervision (PRKR)

    4 Ratings

    latest: Sell 8 months ago



    Fuelcell Energy (FCEL)

    1 Ratings

    latest: Sell a year ago



    Parametric Sound (HEAR)

    1 Ratings

    latest: Sell a year ago



    Lee Enterprises Inc. (LEE)

    1 Ratings

    latest: Sell a year ago



    Affymax (AFFY)

    4 Ratings

    latest: Sell a year ago



    Celsion Corp. (CLSN)

    5 Ratings

    latest: Sell a year ago



    Uni-Pixel (UNXL)

    1 Ratings

    latest: Sell a year ago



    CVD Equipment (CVV)

    1 Ratings

    latest: Sell 2 years ago



    Exact Sciences (EXAS)

    1 Ratings

    latest: Sell 2 years ago



    Oncothyreon (ONTY)

    1 Ratings

    latest: Buy 4 years ago

    Sentiment: Strong Buy

  • They are recommended by the same Analyst
    Whom I consider to be on top of his game.
    Jonathan Aschoff's Ratings


    Average Return

    Average return of the 150 recommendations in the
    15.1 Percent

    following each stock rating.


    Success Rate

    93 out of 150 recommendations had positive returns in the
    Click to change1 Year 63 Percent

    following each stock rating.

    OHR Pharmaceutical (OHRP)

    6 Ratings

    latest: Buy Price Target: $34 Today


    WaferGen Bio systems (WGBS)

    3 Ratings

    latest: Buy Price Target: $11 4 days ago


    Rockwell Med. (RMTI)

    8 Ratings

    latest: Sell Price Target: $4 3 days ago



    Progenics (PGNX)

    5 Ratings

    latest: Buy Price Target: $11 3 days ago



    Keryx Biopharma (KERX)

    12 Ratings

    latest: Buy Price Target: $26 3 days ago






    BioMarin (BMRN)

    4 Ratings

    latest: Hold 4 days ago

    Sentiment: Strong Buy

  • Reply to

    WHere is ADAM F.'s Hate Twit?

    by jg7320 Mar 2, 2015 8:44 AM
    marketjudge marketjudge Mar 2, 2015 8:59 AM Flag

    Don't waste your time focusing on them. Lets talk stock, based on the news today I believe that a buyout or partnership is coming. Either way this is a good stock to be in, do to its ability to show great value in its pipeline. The addition of a strong management teem, shows me that more value is being added to the stock.
    Look for a run up to the $9. to 9.50 range. When, not if, we get more news, we will see the stock go over the $10 mark. To give everyone an example of the potential stock price movement, please look at OCUL.

    Sentiment: Strong Buy

NQ
3.86+0.02(+0.52%)May 1 4:02 PMEDT